Related references
Note: Only part of the references are listed.Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Jason Fangusaro et al.
LANCET ONCOLOGY (2020)
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro et al.
LANCET ONCOLOGY (2019)
TRAMETINIB FOR THE TREATMENT OF RECURRENT/PROGRESSIVE PEDIATRIC LOW GRADE GLIOMA: A SINGLE INSTITUTION EXPERIENCE
Neevika Manoharan et al.
NEURO-ONCOLOGY (2019)
Trametinib Induces Neurofibroma Shrinkage and Enables Surgery
Pia Vaassen et al.
NEUROPEDIATRICS (2019)
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
Sebastien Perreault et al.
BMC CANCER (2019)
Emerging therapeutic targets for neurofibromatosis type 1
James A. Walker et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB
Eric Bouffet et al.
NEURO-ONCOLOGY (2018)
Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies
Lars M. Wagner et al.
PEDIATRIC BLOOD & CANCER (2018)
Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I/IIa study.
Geoffrey Brian McCowage et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Trametinib for progressive pediatric low-grade gliomas
Maria Kondyli et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response
Catherine Miller et al.
JOURNAL OF NEUROSURGERY-PEDIATRICS (2017)
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee et al.
NEURO-ONCOLOGY (2017)
Ocular toxicity due to Trametinib and Dabrafenib
Stephanie Sarny et al.
BMC OPHTHALMOLOGY (2017)
MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children
Veronica A. Kinsler et al.
BRITISH JOURNAL OF CANCER (2017)
Phase II Weekly Vinblastine for Chemotherapy-Naive Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study
Alvaro Lassaletta et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma
Shakeel Modak et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2015)
Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas
Catherine Louise Penman et al.
FRONTIERS IN ONCOLOGY (2015)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Nancy Ratner et al.
NATURE REVIEWS CANCER (2015)
Efficacy of bevacizumab plus irinotecan in children with recurrent Low-grade gliomas-a Pediatric Brain Tumor Consortium study
Sridharan Gururangan et al.
NEURO-ONCOLOGY (2014)
A phase I study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.
Anuradha Banerjee et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for imaging tumor response in neurofibromatosis clinical trials
Eva Dombi et al.
NEUROLOGY (2013)
Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency
Wendy L. See et al.
CANCER RESEARCH (2012)
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
Joann L. Ater et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1
Carlos E. Prada et al.
JOURNAL OF PEDIATRICS (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Frequency and Associated Clinical Deficits
Rosa Nguyen et al.
JOURNAL OF PEDIATRICS (2011)
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations
Judith Jeuken et al.
ACTA NEUROPATHOLOGICA (2007)
Management of head and neck plexiform neurofibromas in pediatric patients with neurofibromatosis type 1
JB Wise et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2005)
Share Paper
